A direct quote from the source article
People at highest risk of developing severe disease include those who are immunosuppressed (for example, as a result of chemotherapy or having had an organ transplant), or who have other conditions such as heart disease, respiratory disease, diabetes, or neurological conditions.
The draft guidance means they will have access to treatments taken either at home or in hospital. It recommends 3 medicines as options for treating COVID-19 in adults:
Paxlovid (also called nirmatrelvir plus ritonavir and made by Pfizer);
Xevudy (also called sotrovimab and made by GlaxoSmithKline); and
RoActemra (also called tocilizumab and made by Roche).
As people with kidney problems looking for a transplant may have a reduced immunity and are therefore more likely to catch COVID-19, it's nice to know that NICE is looking into safer treatments.
